Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorKarina, M.en
dc.contributor.authorBobos, M.en
dc.contributor.authorXiros, N.en
dc.contributor.authorPentheroudakis, G.en
dc.contributor.authorKafiri, G.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorVrettou, E.en
dc.contributor.authorFountzilas, G.en
dc.rightsDefault Licence-
dc.subjectAntineoplastic Agents/*therapeutic useen
dc.subjectCamptothecin/*analogs & derivatives/therapeutic useen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCohort Studiesen
dc.subjectColorectal Neoplasms/*drug therapy/*enzymology/genetics/surgeryen
dc.subjectDNA Topoisomerases, Type I/genetics/*metabolismen
dc.subjectMiddle Ageden
dc.subjectThymidylate Synthase/genetics/*metabolismen
dc.subjectTreatment Outcomeen
dc.subjectYoung Adulten
dc.titleTopoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapyen
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.abstractBACKGROUND: Thymidylate synthase (TS) and Topoisomerase I (Topo I) are significant biomarkers in colorectal cancer (CRC). We aimed to study the expression of TS and Topo I in patients with resected CRC who received adjuvant chemotherapy and correlated it with clinical outcome. METHODS: All patients diagnosed with CRC between 1989 and 2007 and treated with adjuvant chemotherapy within Hellenic Cooperative Oncology Group's (HeCOG) protocols, were identified. Archival paraffin-embedded tumor tissues were used for immunohistochemical detection of TS and Topo I. Immunohistochemistry was performed on tissue microarray slides using monoclonal antibodies against TS and Topo I. The results were correlated with survival (OS) and disease free survival (DFS). RESULTS: A cohort of 498 patients with a median age of 61 years and Dukes' stage B (49%) and C (51%) fulfilled the criteria of the study. All patients received adjuvant 5-FU-based chemotherapy, 38% irinotecan-containing. Positive TS and Topo I expression was found in 43% and 48% of cases, respectively. Five-year OS was 74% and DFS was 68%. In univariate analysis no association of TS and Topo I expression with OS and DFS was identified. In multivariate analysis however, Topo I expression was associated with a reduced risk of death (HR = 0.61, 95% CI 0.42-0.88, p = 0.009). In the irinotecan-treated subgroup, those patients who expressed Topo I had a better OS (HR = 0.47, 95% CI 0.23-0.94, p = 0.033). CONCLUSION: Patients with resected CRC expressing Topo I seem to benefit from irinotecan-containing adjuvant chemotherapy. However randomised prospective trials are needed to confirm these results.en
heal.journalNameBMC Canceren
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Pentheroudakis-2009-topoisomerase I but.pdf1.13 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons